This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traczewski, M. M.
Right arrow Articles by Brown, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traczewski, M. M.
Right arrow Articles by Brown, S. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 819-821, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.819-821.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients

M. M. Traczewski* and S. D. Brown

The Clinical Microbiology Institute, Inc., Wilsonville, Oregon

Received 7 April 2005/ Returned for modification 9 August 2005/ Accepted 28 November 2005

The in vitro activities of doripenem, imipenem, levofloxacin, piperacillin, ceftazidime, aztreonam, tobramycin, and cefepime were determined for 160 isolates of Pseudomonas aeruginosa (82 from cystic fibrosis [CF] patients) and 34 isolates of Burkholderia cepacia. Doripenem MIC90s were lower than those of all other comparative agents against all isolates combined and against all P. aeruginosa isolates. Doripenem was as active as levofloxacin and 2- to 32-fold more active than the other comparative agents against B. cepacia.

* Corresponding author. Mailing address: The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070. Phone: (503) 682-3232. Fax: (503) 682-2065. E-mail: mtrac{at}clinmicroinst.com.

Antimicrobial Agents and Chemotherapy, February 2006, p. 819-821, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.819-821.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • El Solh, A. A., Alhajhusain, A. (2009). Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 64: 229-238 [Abstract] [Full Text]  
  • Baughman, R. P. (2009). The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24: 230-241 [Abstract]  
  • Kim, A., Banevicius, M. A., Nicolau, D. P. (2008). In Vivo Pharmacodynamic Profiling of Doripenem against Pseudomonas aeruginosa by Simulating Human Exposures. Antimicrob. Agents Chemother. 52: 2497-2502 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»